Autopsy report · NCT04358068

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

“Slow enrollment and lack of community enthusiasm”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 months before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor type

US National Institutes of Health

Conditions

COVID-19; SARS-CoV 2

Interventions

Hydroxychloroquine (HCQ); Azithromycin (Azithro); Placebo for Hydroxychloroquine; Placebo for Azithromycin

Participants

20

Sites

11

Countries

United States

Trials that died the same way

• Lumbar Disc Herniation Outcome Measures
  “Slow/low enrollment” (84% match in meaning)
• Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation
  “slow enrollment” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.